PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Lung cancer has traditionally been associated with advanced age; however, its increasing incidence among young adults raises concerning questions regarding its etiology and unique considerations for ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

Under-reporting of treatment-related adverse events is commonplace in cancer drug trials, which are often accompanied by terms that downplay the seriousness of these events. 1 - 3 Cardiovascular ...

Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's ...

PURPOSEWe conducted a randomized controlled trial (SURF-RCT) to evaluate the efficacy of surgery versus radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Simultaneously, eligible ...

The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) ...

Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching The following represents disclosure information ...

PURPOSETo update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).METHODSASCO convened an Expert Panel to update the 2020 ...

Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral ...